Bristol-Myers hands over $100M in cash for a new fibrosis drug, beefing up NASH focus
It’s not all checkpoints all the time at Bristol-Myers Squibb. The big biotech has been ramping up an ambitious effort in fibrosis and NASH and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
